Navigation Links
New drug candidates show promise for cure for Chagas disease
Date:12/26/2013

A team of researchers from Canada has developed a class of compounds which may help eradicate a neglected tropical disease that is currently hard to kill in its chronic form. The research was published ahead of print in Antimicrobial Agents and Chemotherapy.

Chagas disease or American trypanosomiasis, caused by Trypanosoma cruzi, affects about 18 million people living mostly in Latin America. The parasite is transmitted to humans by blood-sucking reduviid bugs, also known as kissing bugs due to their predilection for feeding on the faces of their victims. In the United States, Chagas disease is considered one of the neglected parasitic infections, a group of five parasitic diseases that have been targeted by CDC for public health action.

"While historically infection was largely confined to poor and rural populations in Central and South America, it has been emerging in the U.S., Canada, Europe, Japan, and Australia, due to immigration, and nonvectorial transmission is becoming a public health threat," says Deborah Nicoll-Griffith of the Merck Frosst Centre for Therapeutic Research in Kirkland, Quebec, a researcher on the study. One 2005 estimate put the number of people infected within the U.S. at 300,000 (1/1000).

There are two phases of Chagas disease: the acute phase and the chronic phase. Both phases can be symptom free or life threatening. Left untreated the disease can lead to cardiac and digestive disorders, as the parasite burrows into the heart, esophagus and colon tissue where it causes damage over time.

The current standard of care, the drug benznidazole, has significant activity against the parasite during the acute phase, but is less effective once the disease becomes chronic.

Efforts to find new drugs focus on disrupting an enzyme, cruzipain, which the parasite uses for digestion, to produce other cellular machinery, to evade the host's immune system, and to invade heart and gastrointestinal tissues.

Nicoll-Griffith and her colleagues identified two compounds known as reversible cysteine protease inhibitors that fit cruzipain like jigsaw puzzle pieces, jamming the enzyme. In the study, they tested the efficacy of the compounds in mice against that of benznidazole. While all treatment groups showed a marked reduction in parasite burden, in all tissues, the two experimental compounds had greater cure rates of acute infections (90% and 78%) compared to benznidazole (71%.)

"The efficacy shown in these T. cruzi murine studies suggests that nitrile-containing cruzipain inhibitors show promise as a viable approach for a safe and effective treatment of Chagas disease," write the researchers.


'/>"/>

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology
Source:Eurekalert

Related medicine news :

1. Innovative Screening Strategy Swiftly Uncovers New Drug Candidates, New Biology
2. Dissertation Pal Introduces Statistics Help for Doctoral Candidates
3. Women's Strike Force Announces First Fund Distribution to Virginia House of Delegates Candidates for November Race
4. Issue III registry defines best syncope candidates for cardiac pacing
5. Genetic variations may help identify best candidates for preventive breast cancer drugs
6. Drugs targeting blood vessels may be candidates for treating Alzheimers
7. NIH-funded researchers begin trial of Shigella vaccine candidates
8. Katon Direct, a Healthcare Micro-Marketing Solutions Company, Launches Their New Website, Innovating the way Healthcare Companies Find the Most Qualified Candidates
9. Presidential candidates should address childhood obesity and bullying, poll says
10. Novel drug candidates offer new route to controlling inflammation
11. With Over 12 Million Christmas Wishes Viewed at 123Greetings.com Last Year, Christmas 2013 Promises Even More Cheers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology: